Thelansis

Chronic Immune Thrombocytopenia (ITP) Market Outlook Thelansis’s “Chronic Immune Thrombocytopenia (ITP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Immune Thrombocytopenia (ITP) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the g...

Chronic Immune Thrombocytopenia (ITP) Market Outlook Thelansis’s “Chronic Immune Thrombocytopenia (ITP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Immune Thrombocytopenia (ITP) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Chronic Immune Thrombocytopenia (ITP) Overview Chronic immune thrombocytopenia (ITP) is an autoimmune disease characterized by persistent low platelet counts, which leads to a high risk of uncontrolled bleeding. More severe symptoms include serious bleeding-related episodes (BREs), such as gastrointestinal bleeding, intracranial hemorrhage (ICH) and intra- or post-operative hemorrhage, which ar...

 Chronic immune thrombocytopenia (ITP) is an autoimmune disease characterized by persistent low platelet counts, which leads to a high risk of uncontrolled bleeding. More severe symptoms include serious bleeding-related episodes (BREs), such as gastrointestinal bleeding, intracranial hemorrhage (ICH) and intra- or post-operative hemorrhage, which are associated with morbidity, mortality and diminished HRQoL. High mortality of Chronic immune thrombocytopenia (ITP) patients reason include severe BREs, infection, cardiovascular disease and hematologic cancer. The risk of ICH in ITP patients has been estimated at 1.5% for adults and 0.5% for children, and the risk of severe (non-ICH) bleeding is estimated at 3–20% in children and approximately 10% in adults. The risk of fatal hemorrhage has been estimated at 0.4% per year in patients 60 years. ·        In the United States, the incidence of ITP in adults varies between 16 and 39 cases per million adults ...

 Chronic immune thrombocytopenia (ITP) is an autoimmune disease characterized by persistent low platelet counts, which leads to a high risk of uncontrolled bleeding. More severe symptoms include serious bleeding-related episodes (BREs), such as gastrointestinal bleeding, intracranial hemorrhage (ICH) and intra- or post-operative hemorrhage, which are associated with morbidity, mortality and diminished HRQoL. High mortality of Chronic immune thrombocytopenia (ITP) patients reason include severe BREs, infection, cardiovascular disease and hematologic cancer. The risk of ICH in ITP patients has been estimated at 1.5% for adults and 0.5% for children, and the risk of severe (non-ICH) bleeding is estimated at 3–20% in children and approximately 10% in adults. The risk of fatal hemorrhage has been estimated at 0.4% per year in patients 60 years. ·        In the United States, the incidence of ITP in adults varies between 16 and 39 cases per million adults ...